Figure 2.

Osmotin reduced amyloid burden by inhibiting SREBP2 (sterol regulatory element-binding protein 2) expression in amyloid precursor protein/presenilin 1 (APP/PS1) mice. (a) Western blot analysis of SREBP2, BACE1, APP and amyloid-β (Aβ) levels in hippocampal and cortex extracts from 5-, 9- and 12-month-old wild-type (WT) and vehicle (Veh)- or osmotin (Os)-treated (for a short time) APP/PS1 mice. Representative blots and histograms depicting analyses of band density relative to WT bands are shown. The membranes were reprobed for β-actin as a housekeeping control. The bars indicate the mean±s.e.m. (n=5/group). (b, c) Enzyme-linked immunosorbent assay (ELISA) histograms (relative) of soluble (b) Aβ_1–42 and (c) Aβ_1–40 in cortex and hippocampal brain homogenates of APP/PS1 mice with or without osmotin treatment. All of the methods and procedures recommended by the manufacturer were followed, and experiments were performed in triplicate. (d, e) Fluorescence images with relative density histograms of cortex and hippocampal regions of 12- and 16-month-old Veh- and Os-treated (4 weeks) APP/PS1 mice, indicating the localization of (d) Aβ plaques and (e) Aβ (6E10) aggregates. Significance: *P<0.05, **P<0.01 and ***P<0.001.